Pittenger & Anderson’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.2K Hold
1,000
– – ﹤0.01% 383
2026
Q2
$17K Hold
1,000
– – ﹤0.01% 377
2026
Q1
$14.8K Hold
1,000
– – ﹤0.01% 383
2025
Q4
$16K Hold
1,000
– – ﹤0.01% 379
2025
Q3
$11K Sell
1,000
-1,000
-50% -$10.9K ﹤0.01% 361
2025
Q2
$16.9K Buy
2,000
+1,000
+100% +$8.02K ﹤0.01% 338
2025
Q1
$8.04K Hold
1,000
– – ﹤0.01% 364
2024
Q4
$8.98K Hold
1,000
– – ﹤0.01% 367
2024
Q3
$7.33K Hold
1,000
– – ﹤0.01% 385
2024
Q2
$5.71K Hold
1,000
– – ﹤0.01% 395
2024
Q1
$5.01K Hold
1,000
– – ﹤0.01% 388
2023
Q4
$8.99K Hold
1,000
– – ﹤0.01% 374
2023
Q3
$7.77K Hold
1,000
– – ﹤0.01% 361
2023
Q2
$9.7K Hold
1,000
– – ﹤0.01% 363
2023
Q1
$11K Hold
1,000
– – ﹤0.01% 348
2022
Q4
$4.32K Hold
1,000
– – ﹤0.01% 387
2022
Q3
$8K Hold
1,000
– – ﹤0.01% 349
2022
Q2
$10K Hold
1,000
– – ﹤0.01% 341
2022
Q1
$12K Hold
1,000
– – ﹤0.01% 341
2021
Q4
$23K Hold
1,000
– – ﹤0.01% 304
2021
Q3
$22K Hold
1,000
– – ﹤0.01% 314
2021
Q2
$13K Hold
1,000
– – ﹤0.01% 320
2021
Q1
$13K Hold
1,000
– – ﹤0.01% 310
2020
Q4
$14K Buy
+1,000
New +$14.6K ﹤0.01% 300

Other funds holding AUPH

Pittenger & Anderson's AUPH Position: Q3 2026 in Review

Pittenger & Anderson held its Aurinia Pharmaceuticals (AUPH) position steady in Q3 2026 at 1,000 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Pittenger & Anderson first reported a position in AUPH in Q4 2020 and has held it in 24 quarters since. The position peaked at $23K in Q4 2021. 277 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Pittenger & Anderson held 1,000 shares of Aurinia Pharmaceuticals worth $16.2K as of Q3 2026.
  • Pittenger & Anderson left its Aurinia Pharmaceuticals share count unchanged in Q3 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Pittenger & Anderson's portfolio in Q3 2026, its #383 holding.
  • Pittenger & Anderson first reported a position in Aurinia Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Pittenger & Anderson's Aurinia Pharmaceuticals position peaked at $23K in Q4 2021.
  • 277 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Pittenger & Anderson's 13F filing for Q3 2026, filed 2 Nov 2026.